Bertilimumab, a humanized monoclonal antibody against CCL11, is currently in clinical trials for treating severe allergic disorder, vernal keratoconjunctivitis, and inflammatory bowel disease [34]. This evidence concerns the gene CCL11 and inflammatory bowel disease.